Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980–2022

Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio, John H. Powers

Open source

DOI
10.1038/s41598-024-53554-7
Published
2024-02-09
Container
Scientific Reports
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41598-024-53554-7,
  title = {Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980–2022},
  author = {Enrique Seoane-Vazquez and Rosa Rodriguez-Monguio and John H. Powers},
  year = {2024},
  journal = {Scientific Reports},
  doi = {10.1038/s41598-024-53554-7},
  url = {https://doi.org/10.1038/s41598-024-53554-7}
}

RIS

TY  - JOUR
TI  - Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980–2022
AU  - Enrique Seoane-Vazquez
AU  - Rosa Rodriguez-Monguio
AU  - John H. Powers
PY  - 2024
JO  - Scientific Reports
DO  - 10.1038/s41598-024-53554-7
UR  - https://doi.org/10.1038/s41598-024-53554-7
ER  - 

APA

Seoane-Vazquez, E., Rodriguez-Monguio, R., & Powers, J. H. (2024). Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980–2022. Scientific Reports. https://doi.org/10.1038/s41598-024-53554-7

Source records